ProCE Banner Activity

Tailored Education on TROP-2‒Targeting ADCs in NSCLC: My Reflections on a Small-Group Collaborative Learning Experience

Clinical Thought

Edward B. Garon, MD, MS, discusses his experience leading a small-group collaborative learning session on the management of advanced NSCLC and potential role of novel TROP-2‒targeting ADCs. 

Released: February 29, 2024

Share

Faculty

Edward B. Garon

Edward B. Garon, MD, MS

Professor
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Co-Director of Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Disclosure

Primary Author

Edward B. Garon, MD, MS

Professor
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Co-Director of Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California

Edward B. Garon, MD, MS: consultant/advisor: AbbVie, Arcus, ArriVent, AstraZeneca, Atreca, Black Diamond, BridgeBio, Bristol Myers Squibb, EMD Serono, Gilead, Hookipa, I-Mab, LianBio, Lilly, Merck, Merus, Novartis, Nuvalent, Pfizer, Regeneron, Sanofi, Seagen, Sensei, Strata, Sumitomo, Summit, Synthekine; researcher: ABL-Bio, ArriVent, AstraZeneca, BridgeBio, Bristol Myers Squibb, Daiichi Sankyo, EMD Serono, Genentech, Gilead, Iovance, Lilly, Merck, Mirati, Novartis, Prelude, Regeneron, Synthekine, TILT Biotherapeutics; other financial or material support: A2 Bio, Novartis.